Array BioPharma Gets $85M From Novartis

Boulder-based Array Biopharma said this morning that it has received $85M from Novartis, as part of a licensing deal with the biotech giant. Array Biophrma said it has granted Novartis a global, exclusive license to its binimetinib product, and global rights to its encorafenib product. Both of those drugs are being targeted for treating cancer.